Last reviewed · How we verify
NCT06372704: HIFEM for PPI
Is the HIFEM Procedure an Effective Treatment for Men With Post-prostatectomy Incontinence?
trial testing HIFEM in Prostate Cancer in 27 participants. Completed in 5 April 2024.
1 April 2024
Quick facts
| Lead sponsor | Kirsehir Ahi Evran Universitesi |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 27 |
| Start date | 1 February 2024 |
| Primary completion | 1 April 2024 |
| Estimated completion | 5 April 2024 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- HIFEM
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
- Incontinence — all drugs for Incontinence →
- Pelvic Floor Muscle Weakness — all drugs for Pelvic Floor Muscle Weakness →
Sponsor
Kirsehir Ahi Evran Universitesi — full company profile →
Who can join
Adults 63 to 70, male only, with Prostate Cancer or Incontinence. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Urinary incontinence after radical prostatectomy surgery is a common condition that negatively affects daily life. Patients often experience discomfort due to urine leakage and the resulting need to use pads daily. This study aimed to evaluate the efficacy and safety of high-intensity focused electromagnetic technology used therapeutically in patients with urinary incontinence after radical prostatectomy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06372704
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of HIFEM
Trials testing the same drug.
- NCT06532292 — Physical Therapy Intervention for Pelvic Organ Prolapses · NA · recruiting
- NCT05500300 — Electrical Stimulation With Different Currents and Electromagnetic Fields · NA · unknown
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other Kirsehir Ahi Evran Universitesi trials
Trials by the same sponsor.
- NCT07506915 — The Effect of Cognitive Behavioral Therapy · NA · enrolling by invitation
- NCT07502248 — PENG Block With or Without PPD Block for Postoperative Analgesia After Total Hip Arthroplasty · NA · not yet recruiting
- NCT07438392 — Tecar Therapy in Chronic Knee Osteoarthritis · NA · not yet recruiting
- NCT07450742 — Digital Storytelling and Mother's Knowledge and Attitudes Towards Newborn Screning · NA · not yet recruiting
- NCT07414017 — Comparison of Focus of Attention in Virtual Reality-Based Exercise Training in Older Adults With Low Back Pain · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06372704 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kirsehir Ahi Evran Universitesi
- Last refreshed: 24 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06372704.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing